Oregon Drug Use Review / Pharmacy & Therapeutics Committee
Thursday, September 27, 2018
1:00 p.m. – 5:00 p.m.
DXC Building, 4070 27th Ct
Salem, OR 97301

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9).

Members Present: Kelley Burnett, D.O.; Tracy Klein, PhD, FNP; Caryn Mickelson, PharmD; Stacy Ramirez, PharmD; James Slater, PharmD; Cathy Zehrung, RPh

Members Present by Phone: Dave Pass, MD

Staff Present: Richard Holsapple, RPh; Roger Citron, RPh; Trevor Douglass, DC, MPH; Sarah Servid, PharmD; Dee Weston; Julia Page, PharmD; Jonnaliz Corbett; David Engen, PharmD

Staff Present by Phone: Megan Herink, PharmD

Audience: Rick Frees, Vertex; Steve Nemiron, Kartini Clinic*; Lisa Allen, Vertex*, Jake Mazzola, AllCare; Keri Smith, ViiV; Steve Kimball, Actellion; Allen Hammagren, AbbVie; Nik Seiffer, Sunovion*; Deron Groth, Teva; Jeana Colabiachi, Sunovion; Margaret Olmon, AbbVie*; Jason Way; Emily Shephard; Danielle Shannon, WFP Health Authority; Sylvia Churchill, Amgen*; Camille Kerr, Amgen; Valerie Ng, Indivior; Tim McFerror, Allkermes; Paul Thompson, Allkermes; Randy Blom, MD, Grane Ronde Clinic*; Stuart O’Briochta, Gilead*; Mary Kemhus, Novartis; Marine Schmitt, CareOregon; Kali Schweitler, CareOregon; Laura Jeffcoat, AbbVie; Robin Traver, Umpqua Health Alliance; Amy Burns, AllCare; Lisa Talbott, Gilead; Lorren Sandt, Caring Ambassadors*; Kurt Jensen, Caring Ambassadors*; Kent Benner, The Oregon Clinic*; Andrew Seamen, MD, Oregon Health Sciences University*; BJ Cavnor, One in Four*

(*) Provided verbal testimony

Written testimony provided: Posted to OSU Website
I. CALL TO ORDER

A. The meeting was called to order at approximately 1:05 pm. Introductions were made by Committee members and staff. No new conflict of interests were declared.
B. Dr. Douglass provided a department update and legislative update.
C. Approval of Agenda and Minutes

II. CONSENT AGENDA TOPICS

A. Approval of agenda and July minutes
B. Overactive Bladder DERP Summary
   Recommendation:
   No further review or research needed at this time
   Evaluate comparative costs in executive session
C. Oral and Parenteral Antipsychotics Literature Scan
   Recommendation:
   No changes to the PDL are recommended based on efficacy or safety data
   Evaluate comparative costs in executive session
D. Pancreatic Enzymes Literature Scan
   Recommendation:
   No changes to the PDL are recommended based on efficacy or safety data
   Evaluate comparative costs in executive session

ACTION: Motion to approve, 2nd, All in Favor

III. PREFERRED DRUG LIST NEW BUSINESS

A. Pulmonary Arterial Hypertension Class Update
   Dr. Servid presented the proposal to update the prior authorization (PA) criteria to include contraindications for riociguat in patients with idiopathic interstitial pneumonias and evaluate comparative costs in executive session.
   ACTION: Motion to approve, 2nd, all in favor

B. Attention Deficit Hyperactivity Disorder Literature Scan
   Dr. Page presented the proposal to update the guanfacine extended-release dosing in Table 2 in the PA criteria to clarify FDA-recommended maximum daily doses for monotherapy versus adjunctive therapy and to evaluate comparative costs in executive session.
   ACTION: Motion to approve, 2nd, all in favor

C. Vaginal Antibiotics Drug Class Review
Dr. Sentena presented the class review and recommendation to add the class to the PMPDP and make at least one metronidazole and one clindamycin formulation preferred and to evaluate comparative drug costs in executive session.  
**ACTION:** Motion to approve, 2nd, all in favor

D. Aimovig (erenumab-aooe) New Drug Evaluation  
Dr. Engen presented the NDE and recommendation to add the class to the PMPDP and implement the proposed PA criteria for CGRP antagonists.  
**ACTION:** Modify question #6 to specify migraine prophylaxis classes rather than specific agents; change required specialists to a neurologist or headache specialist; add a question to assess medication overuse assessment in initial approval and renewal criteria.  
Motion to approve, 2nd, all in favor

E. Palynziq (pegvaliase-pqpz) New Drug Evaluation  
Dr. Page presented the NDE and proposal to implement PA criteria for pegvaliase.  
**ACTION:** Add a question to ensure epinephrine is prescribed concurrently  
Motion to approve, 2nd, all in favor

F. Hepatitis C Direct Acting Antivirals Class Update  
Dr. Herink presented the class update and recommendation to remove the treatment requirements for those with substance use disorder, alcohol abuse and illicit injective drug use and incorporate the necessary support into case management programs and to evaluate comparative costs in executive session.  
**ACTION:** Designate a specific meeting in October to discuss expanding HCV coverage  
Motion to approve, 2nd, one opposed, motion passed

IV. DUR NEW BUSINESS

A. Benzodiazepine Policy Evaluation and DERP Report  
Dr. Servid presented the proposal to update the PA criteria to: limit use for treatment of PTSD, allow patients receiving long-term therapy time to taper the dose when appropriate, and require prescribers to provide supporting medical literature and/or appropriate rationale for long-term benzodiazepine use.  
**ACTION:** add requirement to approval and renewal criteria that providers assess PDMP  
Motion to approve, 2nd, all in favor

V. DUR OLD BUSINESS

A. Cystic Fibrosis  
Dr. Herink presented the proposal to update the PA criteria to reflect updated FDA labeling based on approved indications.  
**ACTION:** Motion to approve, 2nd, all in favor

B. Botulinum Toxins Prior to Authorization Update  
Dr. Page presented the proposal to update the PA criteria to reflect current guidelines in the OHA Prioritized List of Health Services.
ACTION: modify step therapy to specify migraine prophylaxis classes rather than specific agents.
Motion to approve, 2nd, all in favor

VI. EXECUTIVE SESSION

Present in room: Kelley Burnett, D.O.; Tracy Klein, PhD, FNP; Caryn Mickelson, PharmD; Stacy Ramirez, PharmD; James Slater, PharmD; Cathy Zehrung, RPh; Richard Holsapple, RPh; Roger Citron, RPh; Trevor Douglass, DC, MPH; Sarah Servid, PharmD; Dee Weston; Julia Page, PharmD; Jonnaliz Corbett; David Engen, PharmD

VII. RECONVENE FOR PUBLIC RECOMMENDATIONS * After executive session

A. Overactive Bladder DERP Summary
   Recommendation: no changes to the PMPDP

B. Antipsychotics Literature Scan
   Recommendation: Make Vraylar®, Aristada® Initio™, Invega® Sustenna® and Trinza® syringes, and Perseris™ preferred agents on the PMPDP.

C. Pancreatic Enzymes Literature Scan
   Recommendation: Make Zenpep® preferred on the PMPDP.

D. Pulmonary Arterial Hypertension Class Update
   Recommendation: No changes to the PMPDP.

E. Attention Deficit Hyperactivity Disorder Literature Scan
   Recommendation: No changes to the PMPDP.

F. Vaginal Antibiotics Drug Class Review
   Recommendation: Make clindamycin phosphate cream with applicator, clindamycin phosphate vaginal suppositories, and metronidazole gel preferred and to designate all other agents non-preferred on the PMPDP.

G. Hepatitis C Direct Acting Antiviral (DAA) Class Update
   Recommendation: Limit Vosevi use to genotypes where there are no other treatment options available.

   ACTION ON ITEMS A-G: Motion to approve, 2nd, all in favor

H. Request from the Oregon Health Authority for the Committee to make a Hep C DAA secondary recommendation for expanding coverage. The Committee requested more time to deliberate on the criteria and requested a meeting by the end of October.
   ACTION: Motion to approve, 2nd, all in favor

VIII. ADJOURN